BIOMAT Database Logo BIOMAT Database Logo

Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. 1994

F Menichetti, and A Del Favero, and P Martino, and G Bucaneve, and A Micozzi, and D D'Antonio, and P Ricci, and M Carotenuto, and V Liso, and A M Nosari, and T Barbui, and G Fasola, and F Mandelli, and
Istituto di Malattie Infettive, Università di Perugia, Italy.

OBJECTIVE To compare the efficacy and tolerability of fluconazole and oral amphotericin B in preventing fungal infection in neutropenic patients with acute leukemia. METHODS A randomized, controlled, multicenter trial. METHODS 30 hematologic units in tertiary care or university hospitals. METHODS 820 consecutive, afebrile, adult patients with acute leukemia and chemotherapy-induced neutropenia. METHODS Patients were randomly assigned to receive fluconazole, 150 mg, as a once-daily capsule, or amphotericin B suspension, 500 mg every 6 hours. METHODS An intention-to-treat analysis was done for 820 patients: 420 treated with fluconazole and 400 treated with oral amphotericin B. RESULTS Definite systemic fungal infection occurred in 2.6% of fluconazole recipients and 2.5% of amphotericin B recipients; suspected systemic fungal infection requiring the empiric use of intravenous amphotericin B occurred in 16% of fluconazole recipients and 21% of oral amphotericin B recipients, a difference of 5 percentage points (95% CI for difference, -0.02% to 10%; P = 0.07). Superficial fungal infection was documented in 1.7% of fluconazole recipients compared with 2.7% of amphotericin B recipients, a difference of one percentage point (CI of difference, -0.9% to 3%; P > 0.2). The distribution of fungal isolates in systemic and superficial fungal infection was similar in both groups. The overall mortality rate accounted for 10% in both groups. An excellent compliance was documented for 90% of patients treated with fluconazole compared with 72% of those treated with amphotericin B suspension, a difference of 18 percentage points (CI for difference, 13% to 23%). Side effects were documented less frequently in fluconazole than in amphotericin B recipients (1.4% compared with 7%, a difference of 5.6 percentage points; CI for difference, 2% to 8%; P < 0.01). CONCLUSIONS Fluconazole was at least as effective as oral amphotericin B in preventing systemic and superficial fungal infection and the empiric use of amphotericin B in neutropenic patients with acute leukemia but was better tolerated.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009181 Mycoses Diseases caused by FUNGI. Fungus Diseases,Fungal Diseases,Fungal Infections,Fungus Infections,Disease, Fungal,Disease, Fungus,Diseases, Fungal,Diseases, Fungus,Fungal Disease,Fungal Infection,Fungus Disease,Fungus Infection,Infection, Fungal,Infection, Fungus,Infections, Fungal,Infections, Fungus
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute

Related Publications

F Menichetti, and A Del Favero, and P Martino, and G Bucaneve, and A Micozzi, and D D'Antonio, and P Ricci, and M Carotenuto, and V Liso, and A M Nosari, and T Barbui, and G Fasola, and F Mandelli, and
Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies.
January 1993, Mycoses,
F Menichetti, and A Del Favero, and P Martino, and G Bucaneve, and A Micozzi, and D D'Antonio, and P Ricci, and M Carotenuto, and V Liso, and A M Nosari, and T Barbui, and G Fasola, and F Mandelli, and
Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy.
January 1999, Drugs under experimental and clinical research,
F Menichetti, and A Del Favero, and P Martino, and G Bucaneve, and A Micozzi, and D D'Antonio, and P Ricci, and M Carotenuto, and V Liso, and A M Nosari, and T Barbui, and G Fasola, and F Mandelli, and
Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients.
January 2000, The Cochrane database of systematic reviews,
F Menichetti, and A Del Favero, and P Martino, and G Bucaneve, and A Micozzi, and D D'Antonio, and P Ricci, and M Carotenuto, and V Liso, and A M Nosari, and T Barbui, and G Fasola, and F Mandelli, and
Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients.
September 2014, The Cochrane database of systematic reviews,
F Menichetti, and A Del Favero, and P Martino, and G Bucaneve, and A Micozzi, and D D'Antonio, and P Ricci, and M Carotenuto, and V Liso, and A M Nosari, and T Barbui, and G Fasola, and F Mandelli, and
Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients.
January 2002, The Cochrane database of systematic reviews,
F Menichetti, and A Del Favero, and P Martino, and G Bucaneve, and A Micozzi, and D D'Antonio, and P Ricci, and M Carotenuto, and V Liso, and A M Nosari, and T Barbui, and G Fasola, and F Mandelli, and
Management of fungal infection in neutropenic patients with fluconazole.
January 1990, Haematology and blood transfusion,
F Menichetti, and A Del Favero, and P Martino, and G Bucaneve, and A Micozzi, and D D'Antonio, and P Ricci, and M Carotenuto, and V Liso, and A M Nosari, and T Barbui, and G Fasola, and F Mandelli, and
Oral fluconazole compared with bladder irrigation with amphotericin B for treatment of fungal urinary tract infections in elderly patients.
January 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
F Menichetti, and A Del Favero, and P Martino, and G Bucaneve, and A Micozzi, and D D'Antonio, and P Ricci, and M Carotenuto, and V Liso, and A M Nosari, and T Barbui, and G Fasola, and F Mandelli, and
[Comparison of oral fluconazole and amphotericin B prophylaxis against fungal infections in the neutropenic phase of patients treated with antileukemic agents].
January 1990, Mycoses,
F Menichetti, and A Del Favero, and P Martino, and G Bucaneve, and A Micozzi, and D D'Antonio, and P Ricci, and M Carotenuto, and V Liso, and A M Nosari, and T Barbui, and G Fasola, and F Mandelli, and
Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK.
November 1999, PharmacoEconomics,
F Menichetti, and A Del Favero, and P Martino, and G Bucaneve, and A Micozzi, and D D'Antonio, and P Ricci, and M Carotenuto, and V Liso, and A M Nosari, and T Barbui, and G Fasola, and F Mandelli, and
Fluconazole or amphotericin for candidosis in neutropenic patients.
January 1991, Lancet (London, England),
Copied contents to your clipboard!